Evidence map›Paper›PMID 31885217›Full record

Observational studyInternational journal of rheumatic diseases2020

Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea.

Sang-Hoon Lee, Yong-Wook Park, Jung-Yoon Choe, Kichul Shin, Seong-Ryul Kwon, Jin-Hye Cha, Young-Joo Kim, Juneyoung Lee, Tae-Hwan Kim

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Sang-Hoon LeeDepartment of Rheumatology, Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, South Korea.
Yong-Wook ParkDepartment of Rheumatology, Chonnam National University Hospital, Gwangju, Korea.
Jung-Yoon ChoeDepartment of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea.
Kichul ShinDepartment of Rheumatology, SMG-SNU Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-6749-7598
Seong-Ryul KwonDepartment of Rheumatology, Inha University Hospital, Incheon, Korea.
Jin-Hye ChaPfizer Pharmaceuticals Korea Limited, Seoul, Korea.ORCID https://orcid.org/0000-0003-0612-5499
Young-Joo KimPfizer Pharmaceuticals Korea Limited, Seoul, Korea.
Juneyoung LeeDepartment of Biostatistics, Korea University College of Medicine, Seoul, Korea.
Tae-Hwan KimDepartment of Rheumatology, The Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.ORCID https://orcid.org/0000-0002-3542-2276
Korea Pharma (South Korea) · KRChonnam National University Hospital · KRDaegu Catholic University · KRHanyang University Seoul Hospital · KRInha University Hospital · KRKorea University · KRKyung Hee University Hospital at Gangdong · KRSNUH SMG-SNU Boramae Medical Center · KR

Funding

Pfizer Pharmaceuticals Korea Ltd.
6 · The paper itself

Abstract

aimThis study examined the degree of gastrointestinal (GI) risk and patient-reported outcomes including GI-related symptoms, adherence to non-steroidal anti-inflammatory drugs (NSAIDs), disease activity and quality of life (QoL) in patients with ankylosing spondylitis (AS).

methodsCross-sectional, observational study conducted at six nationwide, university-based hospitals of Korea. AS patients treated with NSAIDs for at least 2 weeks were included between March and September 2016. Demographic and clinical data were gathered through a medical chart review and patient survey. GI risk was estimated using Standardized Calculator of Risk for Events (SCORE). NSAIDs adherence was investigated with Morisky Medication Adherence Scale-8 (MMAS-8). Disease activity and QoL were examined with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and EuroQol-3L (EQ-5D, EQ-visual analog scale [EQ-VAS]), respectively. Path analysis was implemented to estimate pathways of GI risk, GI symptoms and NSAIDs adherence to QoL.

resultsA total of 596 patients (age: 38.9 ± 12.6 years, male: 82.1%) participated in the study, of which 33.2% experienced GI symptoms during NSAID treatment, and 34.2% of them showed ongoing GI symptoms upon enrollment. According to SCORE, 37.1% of patients showed moderate to very high GI risk. No patient showed high adherence according to MMAS-8, so 55.3% of patients with moderate adherence were considered adherent. BASDAI and QoL of the total patients were 3.5 ± 2.0, 0.6 ± 0.3 (EQ-5D), and 67.4 ± 19.8 (EQ-VAS), respectively. From path analyses, higher GI risk significantly lowered QoL.

conclusionThis study suggests timely therapeutic strategies should be implemented to manage GI risk during NSAID treatment in order to effectively manage AS.

Indexed as

Patient Reported Outcome MeasuresAdultAnti-Inflammatory Agents, Non-SteroidalCross-Sectional StudiesFemaleGastrointestinal DiseasesHumansMaleMedication AdherenceMiddle AgedQuality of LifeRepublic of KoreaRisk AssessmentRisk FactorsSpondylitis, AnkylosingTreatment OutcomeAnti-Inflammatory Agents, Non-Steroidalankylosing spondylitisgastrointestinal riskNSAIDpatient-reported outcomesquality of life

Identifiers

PMID31885217
PMCPMC7065053
OpenAlexW2997146189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.